AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00525525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients receive 200 mg/m2 for Days 1-5 of every 28 day cycle. Although the calendar days may be slightly altered, the patient should always receive this dose for 5 days within a treatment cycle. If the patient experiences certain toxicities specified in the protocol, Temodar will be held then given at a reduced dose, i.e. 150 mg/m2 Days 1-5.
Study NCT00525525 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Patients receive 200 mg/m2 for Days 1-5 of every 28 day cycle. Although the calendar days may be slightly altered, the patient should always receive this dose for 5 days within a treatment cycle. If the patient experiences certain toxicities specified in the protocol, Temodar will be held then given at a reduced dose, i.e. 150 mg/m2 Days 1-5.
Study NCT02020525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: restrictive transfusion strategy
Description: Patients allocated to the restrictive transfusion strategy were transfused only when their hemoglobin concentration decreased below 7.7 g d dL-1 and were then maintained at hemoglobin concentrations between 7.7 and 9.9 g d dL-1.
Study NCT02020525 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: liberal transfusion strategy
Description: Patients assigned to the liberal strategy were transfused when their hemoglobin concentration fell below 9.9 g dL-1, aiming at maintaining hemoglobin at or above 10 g dL-1.
Study NCT02237508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z7200 without oral activated charcoal
Description: 160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).
Study NCT02237508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler without oral activated charcoal
Description: 320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2).
Study NCT02237508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z7200 with oral activated charcoal
Description: 160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).
Study NCT05633849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SMP group
Description: Participants were instructed to take two 500 mg softgels of LIPINOVA(SPM group) after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
Study NCT05633849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Participants were instructed to take two 500 mg softgels of olive oil placebo after breakfast and two after dinner during the first 6 weeks of the study. During the next 6 weeks, participants were instructed to take one softgel after breakfast and one after dinner. Thus, the treatment period was 12 weeks
Study NCT00740298 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sucrose
Description: sweet taste
Study NCT00740298 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: warmth
Description: warmth
Study NCT02145442 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Obex
Description: Obex® will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during three months. Participants will be not trained about changes of lifestyle on their diets, or physical activity.
Study NCT02237508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler with oral activated charcoal
Description: 320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).
Study NCT01403688 — intervention group
Intervention type: PROCEDURE
Intervention: RPFNA
Description: 1. Baseline RPFNA within 3 month prior to the initial COH cycle or within the first 10 days of the treatment cycle (delete this).~2. Repeat RPFNA if pregnancy is not achieved: 6 to 18 months following baseline assessment~3. Repeat RPFNA if pregnancy is achieved: approximately 12 months after discontinuation of breast feeding
Study NCT03025815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Oral stimulation program consists of the a 15 minutes stimulation program, whereby the first 12 minutes involved stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consists of sucking on a pacifier routinely.
Study NCT03025815 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: sham stimulation program consists of the same researcher placing her hands for 15 minutes.
Study NCT03376256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compuflo Epidural Instrument
Description: Compuflo Epidural Instrument will be used to measure pressure levels in the thoracic epidural space while performing thoracic epidural anesthesia.
Study NCT01527695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER tablet 25 mg AZD3241
Description: 2 tablets twice daily for Day 1
Study NCT01527695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER tablet 100 mg AZD3241
Description: 1-6 tablets twice daily from Day 2 until Day 56±3 days
Study NCT01527695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for AZD3241 25 mg
Description: 2 tablets twice daily for Day 1
Study NCT01527695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for AZD3241 100 mg
Description: 1-6 tablets twice daily from Day 2 until Day 56±3 days
Study NCT03957473 — intervention group
Intervention type: DEVICE
Intervention: Indigo Aspiration System
Description: Indigo Aspiration System with CAT RX Aspiration Catheter and optional Indigo Separator 4
Study NCT04723628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group (telephone counseling)
Description: Then, each patient was given 45-60 minutes of individual instruction. The patient training content was prepared based on the Knowledge, Motivation and Behavioral Skills Model (IMB). A total of 12 weeks of follow-up was performed with a weekly short reminder message and a two-weekly phone call. The research data were collected again at the end of 12 weeks.
Study NCT00812981 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1562902A
Description: new-processed (NP), administered intramuscularly in the deltoid region of the non-dominant arm
Study NCT00812981 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1562902A
Description: comparative-processed (CP), administered intramuscularly in the deltoid region of the non-dominant arm
Study NCT02227316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ibuprofen
Description: Uterine fibroid embolization
Study NCT02227316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: Uterine fibroid embolization
Study NCT02227316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous placebo/Intravenous placebo
Description: Uterine fibroid embolization
Study NCT03877458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088
Description: Taking 1 mix probiotics capsule at bed time everyday for three months.
Study NCT03877458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L. reuteri GL-104
Description: Taking 1 probiotic capsule at bed time everyday for three months.
Study NCT03877458 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking 1 placebo capsule at bed time everyday for three months.
Study NCT04491812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: Elastic Kinesiology Tape
Study NCT04491812 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical therapy program
Description: designed physical therapy program
Study NCT04096040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: μCor
Description: μCor consists of the following components: A) Patch B) Sensor C) Charger D) Data transmission device (Gateway) E) Server Once activated, the wearable Sensor automatically acquires ECG, RF readings, heart rate, respiration rate, activity, and posture measurements.
Study NCT03663569 — intervention group
Intervention type: DRUG
Intervention: Spiolto® Respimat®
Description: Drug
Study NCT03233191 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Mammography
Description: Undergo DM
Study NCT03233191 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Tomosynthesis Mammography
Description: Undergo TM
Study NCT03233191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02974998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Women's Health CoOp (YWHC)
Description: Participants received HTC and engaged in a two-session gender-focused intervention. The intervention included information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal. The intervention also encouraged positive goal-seeking to access linkages to health care within the larger social ecological framework of where the young women live.
Study NCT02974998 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard HTC
Description: Participants received the standard HTC available in South Africa for this population.
Study NCT00526357 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: omega-3 fatty acid
Description: Pharmaceutical grade fish oil administered daily in the form of 10 capsules (5 capsules b.i.d.) each containing 400mg of eicosapentaenoic acid (EPA) and 200mg docosahexanoic acid (DHA) which will equate to a daily dose of 4000 mg of EPA and 2000 mg or DHA. The matched placebo containing a 50/50 mix of soybean and corn oil will be supplied by the same manufacturer (Ocean Nutrition, Canada)
Study NCT04937933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coolant spray (Cryos ®Spray, Phyto Performance, Italy)
Description: The coolant spray treatment method is a cryotherapy non-pharmacological treatment choice.
Study NCT04937933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: saline solution
Study NCT00090220 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Description: qHPV intramuscular injection in three 0.5 mL doses over 6 months in the Base Study or EXT1
Study NCT00090220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Description: qHPV intramuscular injection in three 0.5 mL doses over 6 months in the Base Study or EXT1
Study NCT00090220 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo intramuscular injection in three 0.5 mL doses over 6 months.
Study NCT04598035 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Tests
Description: 1. Blood and Urine laboratory tests~2. ECG and blood pressure for cardiovascular measurements~3. Self-report questionnaires about pain
Study NCT04048551 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum
Description: The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with key stakeholders representing clinics, study staff, and adolescent girls and young women (AGYW) and other formative activities. The training is a whole-site training to address barriers to accessing clinical services by AGYW. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to AGYW in order to reduce stigma-related barriers to healthcare and increase uptake of PrEP and sexual and reproductive health services among AGYW.
Study NCT04048551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum
Description: The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with key stakeholders representing clinics, study staff, and adolescent girls and young women (AGYW) and other formative activities. The training is a whole-site training to address barriers to accessing clinical services by AGYW. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to AGYW in order to reduce stigma-related barriers to healthcare and increase uptake of PrEP and sexual and reproductive health services among AGYW.
Study NCT04048551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Women's Health CoOp (YWHC)
Description: In this study, researchers adapted the Young Women's Health CoOp (YWHC) evidence-based empowerment intervention that addresses issues of gender-based violence (GBV), substance use, and sexual risk to include information about PrEP (pre-exposure prophylaxis) and sexual and reproductive health. AGYW will be provided with comprehensive information and will engage in activities that seek to reduce HIV risk factors and increase PrEP readiness, uptake and adherence.
Study NCT04168021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leg ischemia
Description: potential neuroprotection of ischemia/reperfusion of a peripheral organ or tissue against cerebral I/R injury
Study NCT01482065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP (ResMed S9 autoset CPAP)
Description: A ResMed S9 autoset CPAP device will be utilized throughout the study. Throughout the study intervention period, subjects (for AHI> 15) will be instructed to utilize their CPAP and adherence will be monitored using an automatic meter that is built into the CPAP device.
Study NCT02314260 — intervention group
Intervention type: OTHER
Intervention: bishop score calculation
Description: Assessment of bishop score by vaginal examination
Study NCT02314260 — intervention group
Intervention type: OTHER
Intervention: Trans-vaginal ultrasound
Description: trans-vaginal ultrasound assessment of cervical length.
Study NCT02314260 — intervention group
Intervention type: OTHER
Intervention: Modified bishop score calculation
Description: using the cervical length and the original bishop score to calculate modified bishop score
Study NCT02314260 — intervention group
Intervention type: PROCEDURE
Intervention: labour induction
Description: Induction of labor was carried out as per our hospital's standard protocol.
Study NCT00800774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LASIK
Description: Nine eyes of nine patients (3 male and 6 female) with high anisometropia (>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
Study NCT05704062 — intervention group
Intervention type: PROCEDURE
Intervention: Diffusion Weighted Imaging
Description: Undergo DW-MRI
Study NCT05704062 — intervention group
Intervention type: PROCEDURE
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE-MRI
Study NCT03520153 — intervention group
Intervention type: PROCEDURE
Intervention: Hyperinsulinemic Euglycemic Clamp and 2H20
Description: Test is used to assess insulin effects on hepatic glucose production.
Study NCT02965014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-Face Young Women's CoOp (YWC)
Description: Participants will be offered HIV counseling and testing (HCT) and a two-session face-to-face YWC intervention. The face-to-face sessions will include information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal.
Study NCT02965014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Young Women's CoOp (YWC)
Description: Participants will be offered HIV counseling and testing (HCT) and training on the mHealth application, which will include all content addressed in the face-to-face YWC delivery format. Participants will also be offered a tablet to complete the two-session intervention.
Study NCT02965014 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Counseling and Testing
Description: Participants will be offered standard HIV counseling and testing (HCT).
Study NCT03520153 — intervention group
Intervention type: PROCEDURE
Intervention: Hyperglycemic Clamp
Description: Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.
Study NCT03520153 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Glucose Tolerance Test
Description: The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
Study NCT04734548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ApTOLL
Description: ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatory response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
Study NCT04734548 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White freeze-dried powder which is indistinguishable to ApTOLL for taste, color, texture and size.
Study NCT04641442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAS825
Description: Experimental drug
Study NCT04641442 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT03613675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video games
Description: The 4 videos games consists of:~* Asthmonaut, a desktop game in which the child navigates through different scenarios and interacts with nine characters to learn about asthma symptoms and management (30 minutes)~* Lung Launcher, a mobile game in which the character encounters different asthma triggers (customizable to the child) and the child has to find the correct preventive method to address each trigger (4 minutes)~* Asthma Heroes, a desktop game where the player interacts with several characters to learn about their symptoms, treatment and context, and collects objects to help them manage their asthma (30 minutes)~* Bloïd, a mobile game where the player uses a pressure sensor as an input device to guide a spacecraft and destroy meteorites in its path (4 minutes).
Study NCT04162665 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive short course radiation therapy
Description: Radiation must be livered with adaptive planning and MR gating or CBCT breath hold treatment.
Study NCT04162665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care chemotherapy regimen
Description: The recommendations are CAPOX, FOLFOX, or FLT.
Study NCT02076984 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic incisional or ventral hernia repair
Study NCT03121729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enhanced recovery after surgery
Description: Undergo an enhanced recovery after surgery program
Study NCT02879539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MP3000 sound coding strategy or ACE strategy with lower stimulation
Study NCT03255915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)
Description: TDF-FTC pod-IVR designed to deliver TDF at a target rate of 1 mg d-1 and FTC at a target rate of 2 mg d-1.
Study NCT03499899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAG525
Description: LAG525 was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 400mg every 21 days. For all arms, LAG525 was infused first
Study NCT03499899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Spartalizumab was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 300mg every 21 days. Spartalizumab was infused after LAG525
Study NCT03499899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was a concentrate for solution for intravenous infusion, came in 100mg/mL and was dosed per area under the curve (AUC) 6 every 21 days. Carboplatin was infused once LAG525 and spartalizumab infusions were completed
Study NCT01108341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine hydrochloride
Description: Bendamustine will be administered at 90 mg/m\^2 as a 30-minute intravenous (iv) infusion on days 1 and 2 of each cycle.
Study NCT01108341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab will be administered at 300 mg as an iv infusion on day 1 and 1000 mg on day 8 of cycle 1 and 1000 mg on day 1 of each subsequent cycle.